Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

Phase 1

Completed

Conditions: Melanoma
Anaplastic Thyroid Cancer
Other Solid Tumors
Triple Negative Breast Cancer
Non-small Sell Lung Cancer (NSCLC)

Interventions: Biological: PDR001

First Posted Date: 2015-03-31

Last Posted Date: 2022-08-03

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 319

Registration Number: NCT02404441

Locations: 🇺🇸
The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Johns Hopkins, Baltimore, Maryland, United States
🇺🇸
University of Texas MD Anderson Cancer Center MD Anderson PSC, Houston, Texas, United States
🇺🇸
Oregon Health and Science University SC-10, Portland, Oregon, United States

and more 4 locations

Study to Demonstrate the Efficacy (Including Inhibition of Structural Damage), Safety and Tolerability up to 2 Years of Secukinumab in Active Psoriatic Arthritis

Phase 3

Completed

Conditions: Psoriatic Arthritis

Interventions: Biological: Secukinumab

First Posted Date: 2015-03-31

Last Posted Date: 2020-04-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 997

Registration Number: NCT02404350

Locations: 🇻🇳
Novartis Investigative Site, Ho Chi Minh, Vietnam

A Phase I Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Renal Function

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: osilodrostat

First Posted Date: 2015-03-26

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 15

Registration Number: NCT02399202

Locations: 🇩🇪
Novartis Investigative Site, Berlin, Germany

Study of Efficacy and Safety of Canakinumab in Japanese Patients With SJIA

Phase 3

Completed

Conditions: Systemic Juvenile Idiopathic Arthritis

Interventions: Biological: Canakinumab

First Posted Date: 2015-03-24

Last Posted Date: 2019-09-13

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 19

Registration Number: NCT02396212

Locations: 🇯🇵
Novartis Investigative Site, Sendai-city, Miyagi, Japan

A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)

Phase 3

Completed

Conditions: Plaque Type Psorisis

Interventions: Biological: Secukinumab

First Posted Date: 2015-03-20

Last Posted Date: 2019-04-23

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 434

Registration Number: NCT02394561

Locations: 🇮🇹
Novartis Investigative Site, Napoli, Italy

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: ALK-positive NSCLC

Interventions: Drug: Ceritinib (LDK378)
Drug: Nivolumab

First Posted Date: 2015-03-19

Last Posted Date: 2024-10-11

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 57

Registration Number: NCT02393625

Locations: 🇪🇸
Novartis Investigative Site, Barcelona, Catalunya, Spain
🇺🇸
Mayo Clinic - Arizona, Scottsdale, Arizona, United States
🇺🇸
Massachusetts General Hospital Thoracic Oncolgoy, Boston, Massachusetts, United States

Evaluation of Hepatic Function Impairment on the Pharmacokinetics of LEE011

Phase 1

Completed

Conditions: Normal Hepatic Function
Impaired Hepatic Function

Interventions: Drug: LEE011

First Posted Date: 2015-03-17

Last Posted Date: 2020-12-19

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT02388620

Locations: 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸
University of Miami, Coral Gables, Florida, United States

Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)

Conditions: Heart Failure With Reduced Ejection Fraction (HF-rEF)

First Posted Date: 2015-03-17

Last Posted Date: 2021-02-15

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT02389933

Locations: 🇦🇪
Novartis Investigative Site, Ras Al Khaimah, United Arab Emirates

CINC424A2X01B Rollover Protocol

Phase 4

Active, not recruiting

Conditions: Primary Myelofibrosis
Polycythemia Vera
Thalassemia
Acute Myeloid Leukemia
Graft Versus Host Disease

Interventions: Drug: ruxolitinib
Drug: panobinostat

First Posted Date: 2015-03-12

Last Posted Date: 2025-05-30

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 356

Registration Number: NCT02386800

Locations: 🇹🇷
Novartis Investigative Site, Talas Kayseri, Turkey

A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations

Phase 1

Active, not recruiting

Conditions: Advanced Malignancies That Harbor IDHR132 Mutations

Interventions: Drug: IDH305

First Posted Date: 2015-03-06

Last Posted Date: 2025-03-25

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 166

Registration Number: NCT02381886

Locations: 🇺🇸
Uni Of TX MD Anderson Cancer Cntr, Houston, Texas, United States
🇺🇸
Dana Farber Cancer Institute SC (1), Boston, Massachusetts, United States
🇺🇸
Columbia University Medical Center- New York Presbyterian Onc Dept., New York, New York, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy